Low Foam 5-Type Multi-Enzyme Cleaner Concentrate for Medical Instrument Endoscope

Name: Low Foam 5-Type Multi-Enzyme Cleaner Concentrate for Medical Instrument Endoscope
Brand: Wuhan Snow Medical Disinfectant Co., Ltd.
SKU: 1971318312

Hubei, ChinaWuhan Snow Medical Disinfectant Co., Ltd.

US$23.99-41.00

500 Barrel

Sample price:US$0.00/piece.Request sample

Product profile

Customization

Available

Type

Disinfectant

pH Value

7.5

Model NO.

2500ml

Color

Green, Blue

Shelf Life

2 Years

Features

Low Foam

Transport Package

Carton

Specification

2500ml, 5000ml

Trademark

Snow/OEM

Origin

China

HS Code

3402209000

Company profile

Wuhan Snow Medical Disinfectant Co., Ltd.

Hubei, China

CertifiedBusiness Type: Manufacturer/Factory CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2020-06-12 CertifiedNearest Port: Shanghai Port, Shenzhen PortAverage Response Time: ≤4.47h CertifiedTerms of Payment: LC, T/T, PayPal, etc.

AI-Powered supplier vetting

SummaryWuhan Snow Medical Disinfectant Co., Ltd. is a China-based manufacturer established in 1999, focused on disinfectant and sterilization products. The supplier reports more than 21 years of industry experience, ISO9001 and ISO13485 audits, SGS and other testing or certification claims, multiple production lines, quality-control staff, R&D personnel, and an annual output of 8,000,000 disinfectant pieces. It offers OEM services and exports under self-operated import/export rights, with stated off-peak lead times within 15 workdays and peak-season fulfillment of one month. However, supplier-management-system certification is recorded as NIL, several certification details are incomplete, after-sales support is not described, and the available customer evidence is limited to one buyer name associated with two 2025 shipment records.

Supplier typeThe supplier is explicitly identified as a manufacturer and limited company operating from a stated factory in Wuhan, China. Its business scope and product keywords center on disinfectants, sterilization products, and related chemical or medical applications, with self-operated import/export rights reported since 2020.

CertificationsThe supplier reports ISO9001 and ISO13485 quality-management audits, SGS audit and testing, and qualifications or certificates including FDA, CE, TUV, RoHS, PVoC, and CFS. However, supplier-management-system certification is separately recorded as NIL, and some FDA details are incomplete, so the evidence supports reported product and quality certifications but not a fully verified certification profile.

R&D capabilityThe company describes itself as a high-tech manufacturer with dedicated research and development, supported by university experts and professors, and reports two years of R&D engineer experience. Its stated product development and testing activities support some innovation capability, although the available R&D staffing evidence is limited.

Production capacityThe supplier reports five operating production lines, six to ten quality-control staff, a 4,719.58 m² manufacturing area in one record, and annual production of 8,000,000 disinfectant pieces. It also states that off-peak lead time is within 15 workdays and peak fulfillment is one month, providing explicit evidence of established production operations; the conflicting description of a workshop over 10,000 m² should be clarified.

Customization capabilityThe supplier explicitly states that it offers OEM service in addition to selling self-owned brands. This directly supports customization capability for its disinfectant and sterilization product range, although the slices do not specify minimum order quantities, formulation-development scope, packaging options, or customization lead times.

Client casesTwo shipment records from May 2025 associate the supplier with buyer HOSPITAL SOLUTIONS and products including OPA phthalaldehyde solution and enhanced 2% glutaraldehyde disinfectant. This provides evidence of at least one identifiable buyer relationship and relevant product transactions, but the case evidence is narrow and does not establish a broad customer portfolio.